Multiple Myeloma Coverage from Every Angle

Paul G. Richardson, MD: A New Era for Patients With Newly Diagnosed Multiple Myeloma?

Posted: Monday, June 13, 2022

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses the implications of phase III findings from the DETERMINATION trial and why they may be critical to improving care for patients with newly diagnosed multiple myeloma. The data showed that lenalidomide, bortezomib, and dexamethasone (RVd) with or without autologous stem cell transplant and lenalidomide maintenance to disease progression resulted in the longest median progression-free survival reported for each approach, although no survival benefit has been reported as of yet.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.